AR036950A1 - Composicion farmaceutica - Google Patents
Composicion farmaceuticaInfo
- Publication number
- AR036950A1 AR036950A1 ARP020104020A ARP020104020A AR036950A1 AR 036950 A1 AR036950 A1 AR 036950A1 AR P020104020 A ARP020104020 A AR P020104020A AR P020104020 A ARP020104020 A AR P020104020A AR 036950 A1 AR036950 A1 AR 036950A1
- Authority
- AR
- Argentina
- Prior art keywords
- nanocorpuscles
- metallothionein
- derivatives
- preparing
- aqueous solution
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 abstract 3
- 102000003792 Metallothionein Human genes 0.000 abstract 3
- 108090000157 Metallothionein Proteins 0.000 abstract 3
- 239000007864 aqueous solution Substances 0.000 abstract 3
- 239000003833 bile salt Substances 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000002270 dispersing agent Substances 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 239000000232 Lipid Bilayer Substances 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Comprende una dispersión de nanocorpúsculos en una solución acuosa como dispersante y un alcohol farmacéuticamente aceptable como codispersante o codisolvente, presentando dichos nanocorpúsculos por lo menos una bicapa lipídica que comprende por lo menos una sal biliar o derivados de ésta y por lo menos un fosfolípido de fórmula general (1), donde R1 y R2 son iguales o diferentes entre sí, siendo generalmente restos alifáticos lineales con 12-22 átomos de carbono, pudiendo tener hasta 4 dobles enlaces cis, preferentemente hasta 3 dobles enlaces cis; presentando dichos nanocorpúsculos un diámetro medio inferior a 500 nm; e incluyendo en su interior metalotioneína. El procedimiento de obtención comprende a) preparar una disolución acuosa de por lo menos una sal biliar, o derivados de ésta, y la metalotioneína. El procedimiento de obtención comprende: a)preparar una disolución acuosa de por lo menos una sal biliar, o derivados de ésta, y la metalotioneína; b) preparar una disolución alcohólica del fosfolípido de fórmula general (1); c) homogeneizar conjuntamente ambas disoluciones. La composición farmacéutica tiene aplicación como medicamento, especialmente en el tratamiento de enfermedades neurodegenerativas y neurológicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200102435A ES2196978B1 (es) | 2001-10-26 | 2001-10-26 | Composicion farmaceutica. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036950A1 true AR036950A1 (es) | 2004-10-13 |
Family
ID=8499357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104020A AR036950A1 (es) | 2001-10-26 | 2002-10-24 | Composicion farmaceutica |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040265366A1 (es) |
| EP (1) | EP1439822A1 (es) |
| AR (1) | AR036950A1 (es) |
| ES (1) | ES2196978B1 (es) |
| WO (1) | WO2003035033A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691765B2 (en) * | 2002-06-13 | 2014-04-08 | University Of Tasmania | Metallothionein based neuronal therapeutic and therapeutic methods |
| US20100255080A1 (en) * | 2009-04-02 | 2010-10-07 | Sesvalia Usa, Llc | Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment |
| US8568749B2 (en) * | 2009-04-02 | 2013-10-29 | Sesvalia Usa, Llc | Systems and methods for skin rejuvenation |
| ES2442450B1 (es) * | 2012-08-09 | 2014-12-12 | Enoc Solutions, S.L. | Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100400107B1 (ko) * | 1992-03-23 | 2003-12-24 | 케네트나오유키마츠무라 | 해독제조성물 |
| CA2108622A1 (en) * | 1992-10-19 | 1994-04-20 | Yoko Uchida | Growth inhibitory factor |
| DE4308121A1 (de) * | 1993-03-15 | 1994-09-22 | Rhone Poulenc Rorer Gmbh | Wäßriges Liposomensystem sowie Verfahren zur Herstellung eines derartigen Liposomensystems |
| WO2000038654A1 (en) * | 1998-12-23 | 2000-07-06 | Vallee Bert L | Synthetic and therapeutic methods for the alpha and beta domains of metallothionein |
-
2001
- 2001-10-26 ES ES200102435A patent/ES2196978B1/es not_active Expired - Fee Related
-
2002
- 2002-10-24 AR ARP020104020A patent/AR036950A1/es unknown
- 2002-10-24 WO PCT/IB2002/004477 patent/WO2003035033A1/en not_active Application Discontinuation
- 2002-10-24 EP EP02777670A patent/EP1439822A1/en not_active Withdrawn
- 2002-10-24 US US10/493,615 patent/US20040265366A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2196978A1 (es) | 2003-12-16 |
| WO2003035033A1 (en) | 2003-05-01 |
| US20040265366A1 (en) | 2004-12-30 |
| ES2196978B1 (es) | 2005-03-16 |
| EP1439822A1 (en) | 2004-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60224284T2 (de) | Stabile formulierung von modifiziertem glp-1 | |
| HK1060285A1 (en) | Drug delivery system for photosensitizers | |
| AR036448A1 (es) | Composiciones farmaceuticas de conjugados droga insulina-oligomeros, y metodos para tratar las enfermedades con los mismos | |
| MX2021011242A (es) | Conjugados de vesícula extracelular y usos de estos. | |
| ATE429416T1 (de) | Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen | |
| KR890007718A (ko) | 개선된 암포테리신b 리포좀 제조법 | |
| MXPA05002814A (es) | Formulacion para agentes lipofilicos. | |
| AR023346A1 (es) | Compuestos derivados biciclicos substituidos utiles como agentes contra el cancer, uso de los mismos para preparar un medicamento, composicionesfarmaceuticas y procedimiento de preparacion de los compuestos | |
| PL359624A1 (en) | Clear aqueous anaesthetic composition | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| DE202009019116U1 (de) | Wässrige pharmazeutische Zusammensetzungen, die Borat-Polyol-Komplexe enthalten | |
| JPH06263630A (ja) | ビタミンａ類可溶化点眼剤 | |
| MX2023000614A (es) | Lipidos cationicos para usarse en nanoparticulas lipidicas. | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| ATE308545T1 (de) | Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| AUPQ846900A0 (en) | A vaccine | |
| CA3154947A1 (en) | Antimicrobial organosilanes | |
| AR036950A1 (es) | Composicion farmaceutica | |
| ATE340561T1 (de) | Verwendung von antiseptika zur herstellung von arzneimitteln zur prophylaxe und behandlung von entzündungen im korperinneren des menschen | |
| ES2154806T3 (es) | Formulaciones de compuestos como dispersiones de nanoparticulas en aceites o acidos grasos digeribles. | |
| DE69006259T2 (de) | Hypoallergene anästhesierende/hypnotische steroide Arzneizubereitung. | |
| Ayoob et al. | Preparation, characterization and in vitro toxicity study of antiparasitic drugs loaded onto functionalized MWCNTs | |
| AR074724A1 (es) | Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno | |
| ATE269352T1 (de) | 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung | |
| JP2005075783A (ja) | 難溶性化合物の可溶化または分散化用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |